Drug Trial Radar · NCT04194125
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer
Last checked: Nov 20, 2026Latest source record: Nov 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
25
Planned (sponsor's estimate)
Start
Feb 1, 2019
Primary completion
Jun 30, 2021
Study completion Jan 31, 2022
Sponsor
- Lead sponsor
- University of Warmia and MazuryAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Maria Sklodowska-Curie National Research Institute of Oncology; Medical University of Warsaw; The Diagnostic and Therapeutic Center Gammed; Poland; National Center for Research and Development, Poland
- First posted
- Dec 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-randomized, phase II, open label study. The purpose of this study is to estimate Progression Free Survival (PFS) after treatment with Peptide Receptor Radionuclide Therapy (PRRT) 177Lu-DOTATOC standard dose (up to 4x7,4GBq 177Lu DOTATOC) in combination with capecitabine (CAP) and temozolomide (TEM) - CAPTEM. Patients with advanced, non-resectable and/or progressive gastro-entero-pancreatic neuroendocrine tumors, GEP-NET, (G1, G2), in selected cases with high proliferation index (Ki-67\> 20%, usually below 55%), NETG3, with overexpression of somatostatin receptor (SSTR positive) will be enrolled in the study.
Conditions
- Neuroendocrine Tumors
Interventions
177Lu-DOTATOCDrug
Four administrations of 5,55GBq up to 7,4 GBq 177Lu-DOTATOC will be administered at 8-week intervals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS - Progression Free SurvivalTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centrum Diagnostyczno-Lecznicze Gammed
Warsaw, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.